vs
SunOpta Inc.（STKL）与再鼎医药（ZLAB）财务数据对比。点击上方公司名可切换其他公司
SunOpta Inc.的季度营收约是再鼎医药的1.6倍（$205.4M vs $127.1M），再鼎医药同比增速更快（17.1% vs 16.6%），SunOpta Inc.自由现金流更多（$12.1M vs $-26.7M），过去两年再鼎医药的营收复合增速更高（20.8% vs 7.4%）
SunOpta Inc.是一家跨国企业，主营食品与矿产业务，公司1973年于加拿大创立，目前总部位于美国明尼苏达州伊登普雷里，在相关行业领域拥有多年的运营经验与全球化布局。
再鼎医药是一家创新生物制药企业，专注于肿瘤、自身免疫性疾病、感染性疾病等领域创新疗法的研发、生产与商业化，核心市场覆盖大中华区，与全球多家头部生物科技企业合作，为存在未被满足医疗需求的患者提供治疗方案。
STKL vs ZLAB — 直观对比
营收规模更大
STKL
是对方的1.6倍
$127.1M
营收增速更快
ZLAB
高出0.5%
16.6%
自由现金流更多
STKL
多$38.8M
$-26.7M
两年增速更快
ZLAB
近两年复合增速
7.4%
损益表 — Q3 FY2025 vs Q4 FY2025
| 指标 | | |
|---|---|---|
| 营收 | $205.4M | $127.1M |
| 净利润 | $816.0K | — |
| 毛利率 | 12.4% | 51.0% |
| 营业利润率 | 3.3% | -54.6% |
| 净利率 | 0.4% | — |
| 营收同比 | 16.6% | 17.1% |
| 净利润同比 | 113.1% | — |
| 每股收益（稀释后） | $0.01 | $-0.05 |
绿色 = 该指标领先。财年不对齐时期间可能不同
8季度营收与利润趋势
并排季度历史对比，按日历期对齐，财年错位的公司也能正确匹配
营收STKLZLAB
| Q4 25 | — | $127.1M | ||
| Q3 25 | $205.4M | $115.4M | ||
| Q2 25 | $191.5M | $109.1M | ||
| Q1 25 | $201.6M | $105.7M | ||
| Q4 24 | $193.9M | $108.5M | ||
| Q3 24 | $175.9M | $101.8M | ||
| Q2 24 | $169.5M | $100.1M | ||
| Q1 24 | $184.4M | $87.1M |
净利润STKLZLAB
| Q4 25 | — | — | ||
| Q3 25 | $816.0K | $-36.0M | ||
| Q2 25 | $4.4M | $-40.7M | ||
| Q1 25 | $4.8M | $-48.4M | ||
| Q4 24 | $-8.7M | — | ||
| Q3 24 | $-6.2M | $-41.7M | ||
| Q2 24 | $-5.3M | $-80.3M | ||
| Q1 24 | $2.9M | $-53.5M |
毛利率STKLZLAB
| Q4 25 | — | 51.0% | ||
| Q3 25 | 12.4% | 59.5% | ||
| Q2 25 | 14.8% | 60.6% | ||
| Q1 25 | 15.0% | 63.6% | ||
| Q4 24 | 10.9% | 61.5% | ||
| Q3 24 | 13.0% | 64.1% | ||
| Q2 24 | 12.5% | 64.9% | ||
| Q1 24 | 16.8% | 61.4% |
营业利润率STKLZLAB
| Q4 25 | — | -54.6% | ||
| Q3 25 | 3.3% | -42.3% | ||
| Q2 25 | 5.5% | -50.3% | ||
| Q1 25 | 5.2% | -53.3% | ||
| Q4 24 | 1.4% | -62.6% | ||
| Q3 24 | 0.5% | -66.6% | ||
| Q2 24 | 1.2% | -76.0% | ||
| Q1 24 | 5.5% | -80.7% |
净利率STKLZLAB
| Q4 25 | — | — | ||
| Q3 25 | 0.4% | -31.2% | ||
| Q2 25 | 2.3% | -37.3% | ||
| Q1 25 | 2.4% | -45.8% | ||
| Q4 24 | -4.5% | — | ||
| Q3 24 | -3.5% | -40.9% | ||
| Q2 24 | -3.1% | -80.2% | ||
| Q1 24 | 1.6% | -61.4% |
每股收益（稀释后）STKLZLAB
| Q4 25 | — | $-0.05 | ||
| Q3 25 | $0.01 | $-0.03 | ||
| Q2 25 | $0.03 | $-0.04 | ||
| Q1 25 | $0.04 | $-0.04 | ||
| Q4 24 | $-0.08 | $-0.09 | ||
| Q3 24 | $-0.05 | $-0.04 | ||
| Q2 24 | $-0.04 | $-0.08 | ||
| Q1 24 | $0.02 | $-0.05 |
资产负债表与财务实力
最新季度各公司的流动性、杠杆与账面价值一览
| 指标 | | |
|---|---|---|
| 现金及短期投资手头流动性 | $2.2M | $689.6M |
| 总债务越低越好 | $250.8M | — |
| 股东权益账面价值 | $162.8M | $715.5M |
| 总资产 | $694.1M | $1.2B |
| 负债/权益比越低杠杆越低 | 1.54× | — |
8季度趋势，按日历期对齐
现金及短期投资STKLZLAB
| Q4 25 | — | $689.6M | ||
| Q3 25 | $2.2M | $717.2M | ||
| Q2 25 | $2.2M | $732.2M | ||
| Q1 25 | $2.3M | $757.3M | ||
| Q4 24 | $1.6M | $779.7M | ||
| Q3 24 | $2.9M | $616.1M | ||
| Q2 24 | $3.2M | $630.0M | ||
| Q1 24 | $1.5M | $650.8M |
总债务STKLZLAB
| Q4 25 | — | — | ||
| Q3 25 | $250.8M | — | ||
| Q2 25 | $263.3M | — | ||
| Q1 25 | $260.6M | — | ||
| Q4 24 | $265.2M | — | ||
| Q3 24 | $289.9M | — | ||
| Q2 24 | $303.1M | — | ||
| Q1 24 | $258.8M | — |
股东权益STKLZLAB
| Q4 25 | — | $715.5M | ||
| Q3 25 | $162.8M | $759.9M | ||
| Q2 25 | $159.8M | $791.7M | ||
| Q1 25 | $154.8M | $810.8M | ||
| Q4 24 | $148.6M | $840.9M | ||
| Q3 24 | $155.0M | $667.7M | ||
| Q2 24 | $158.8M | $704.2M | ||
| Q1 24 | $163.6M | $762.2M |
总资产STKLZLAB
| Q4 25 | — | $1.2B | ||
| Q3 25 | $694.1M | $1.2B | ||
| Q2 25 | $704.9M | $1.2B | ||
| Q1 25 | $690.7M | $1.2B | ||
| Q4 24 | $668.5M | $1.2B | ||
| Q3 24 | $699.3M | $985.3M | ||
| Q2 24 | $704.7M | $987.4M | ||
| Q1 24 | $671.8M | $988.4M |
负债/权益比STKLZLAB
| Q4 25 | — | — | ||
| Q3 25 | 1.54× | — | ||
| Q2 25 | 1.65× | — | ||
| Q1 25 | 1.68× | — | ||
| Q4 24 | 1.78× | — | ||
| Q3 24 | 1.87× | — | ||
| Q2 24 | 1.91× | — | ||
| Q1 24 | 1.58× | — |
现金流与资本效率
扣除再投资后实际产生的现金。现金流比净利润更难造假
| 指标 | | |
|---|---|---|
| 经营现金流最新季度 | $16.3M | $-26.0M |
| 自由现金流经营现金流 - 资本支出 | $12.1M | $-26.7M |
| 自由现金流率自由现金流/营收 | 5.9% | -21.0% |
| 资本支出强度资本支出/营收 | 2.1% | 0.5% |
| 现金转化率经营现金流/净利润 | 20.03× | — |
| 过去12个月自由现金流最近4个季度 | $36.4M | $-158.9M |
8季度趋势，按日历期对齐
经营现金流STKLZLAB
| Q4 25 | — | $-26.0M | ||
| Q3 25 | $16.3M | $-32.0M | ||
| Q2 25 | $-4.5M | $-31.0M | ||
| Q1 25 | $22.3M | $-61.7M | ||
| Q4 24 | $33.1M | $-55.8M | ||
| Q3 24 | $17.2M | $-26.8M | ||
| Q2 24 | $-5.6M | $-42.2M | ||
| Q1 24 | $5.3M | $-90.1M |
自由现金流STKLZLAB
| Q4 25 | — | $-26.7M | ||
| Q3 25 | $12.1M | $-35.0M | ||
| Q2 25 | $-9.2M | $-33.9M | ||
| Q1 25 | $9.5M | $-63.2M | ||
| Q4 24 | $24.0M | $-58.4M | ||
| Q3 24 | $11.7M | $-28.2M | ||
| Q2 24 | $-15.3M | $-42.9M | ||
| Q1 24 | $-2.3M | $-91.1M |
自由现金流率STKLZLAB
| Q4 25 | — | -21.0% | ||
| Q3 25 | 5.9% | -30.4% | ||
| Q2 25 | -4.8% | -31.1% | ||
| Q1 25 | 4.7% | -59.9% | ||
| Q4 24 | 12.4% | -53.8% | ||
| Q3 24 | 6.6% | -27.7% | ||
| Q2 24 | -9.0% | -42.9% | ||
| Q1 24 | -1.2% | -104.5% |
资本支出强度STKLZLAB
| Q4 25 | — | 0.5% | ||
| Q3 25 | 2.1% | 2.6% | ||
| Q2 25 | 2.5% | 2.6% | ||
| Q1 25 | 6.3% | 1.5% | ||
| Q4 24 | 4.7% | 2.4% | ||
| Q3 24 | 3.2% | 1.3% | ||
| Q2 24 | 5.7% | 0.7% | ||
| Q1 24 | 4.1% | 1.1% |
现金转化率STKLZLAB
| Q4 25 | — | — | ||
| Q3 25 | 20.03× | — | ||
| Q2 25 | -1.03× | — | ||
| Q1 25 | 4.63× | — | ||
| Q4 24 | — | — | ||
| Q3 24 | — | — | ||
| Q2 24 | — | — | ||
| Q1 24 | 1.83× | — |
财务流量对比
营收 → 毛利润 → 营业利润 → 净利润流向图
业务分部营收拆解
STKL
| Beverages And Broths | $161.4M | 79% |
| Fruit Snacks | $40.9M | 20% |
| Ingredients | $3.1M | 2% |
ZLAB
| Zejula | $56.0M | 44% |
| Other | $21.9M | 17% |
| Nuzyra | $16.0M | 13% |
| Optune | $11.9M | 9% |
| XACDURO | $10.7M | 8% |
| Qinlock | $9.7M | 8% |
| AUGTYRO | $836.0K | 1% |
